Boston Scientific has completed the initial launch of its TAXUSLiberte paclitaxel-eluting coronary stent system.
On January 17, the Company announced that it had launched the stent system in 18 countries. The new product is now fully launched in those countries.
Early physician feedback has been extremely positive, including reaction from physicians doing live cases at the 14th Annual Singapore LIVE course.
“I had the opportunity to use the new TAXUS Liberte stent system during the recent Singapore LIVE course,” said Maurice Buchbinder, M.D., of the Foundation for Cardiovascular Medicine in San Diego. “Despite somewhat challenging anatomy, the TAXUS Liberte stent system performed very nicely, crossing the lesions with ease and conforming to the anatomy very well. The angiographic results were superb. The TAXUS Liberte stent system is a significant advance in drug-eluting stent platform technology, which will enhance percutaneous therapy for more complex coronary anatomy.”
“We are pleased that the feedback has been so positive on this next- generation technology,” said Jim Tobin, President and CEO of Boston Scientific. “The innovative design of the Liberte stent significantly improves deliverability and conformability, and paclitaxel is well-known for its safety and efficacy. The TAXUS Liberte stent system is an important advance in the treatment of coronary artery disease.”
Along with all of the positive feedback, the company has had a big jump in sales.
murdok | Breaking eBusiness News
Your source for investigative ebusiness reporting and breaking news.
